Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARNI versus ARB in elderly patients with acute decompensated HFpEF
ChiCTR2000035327Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sacubitril + valsartan and valsartan in heart failure with preserved ejection fraction (HFpEF) and heart failure (HF) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: NT-proBNP. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
sacubitril + valsartanvalsartan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2000035327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035327.